Indian API Industries. The Strategic Challenges Ahead !!!

 

The global pharmaceutical landscape is undergoing its most aggressive structural realignment in three decades. Driven by post-pandemic de-risking, national security mandates, and technological leaps in biopharma, the global Active Pharmaceutical Ingredient (API) supply chain is pivoting away from monolithic dependency.

At the epicenter of this shift sits India. Long hailed as the "Pharmacy of the World" for finished formulations, India is undergoing an industrial transformation: evolving from an importer of commodity intermediates into an integrated, high-value API and CRDMO powerhouse.

1. Market Trajectory: The Scale-Up (2025–2034)

India’s API sector reached an estimated $20.70 billion in 2026, expanding at an annual compound rate (CAGR) of 7.78% toward a projected $41.60 billion by 2034. While merchant generic APIs continue to represent over 55% of total domestic output, high-value specialty sectors are expanding at double-digit rates.

2. Global Macro Forces: "China+1" and the BIOSECURE Ripple Effect

Global pharmaceutical procurement has moved decisively from a pure "cost-first" paradigm to a "resilience-and-compliance-first" mandate. Two structural drivers dominate boardroom discussions:

[Geopolitical Tension & Supply Volatility]

                  │

                  ▼

   US BIOSECURE Act Implementation (Late 2025/2026)

                  │

  ┌───────────────┴───────────────┐

  ▼                               ▼

Western Biopharma RFP Shift    Western Reshoring Limits

(De-risking Chinese CDMOs)     (High CapEx & Environmental Barriers)

  │                               │

  └───────────────┬───────────────┘

                  ▼

 [India: The Scalable, Compliant "China+1" Beneficiary]

• The BIOSECURE Act Catalyst: Following the codification of the BIOSECURE Act in the United States, global pharmaceutical sponsors have begun migrating early-stage and commercial contract manufacturing away from restricted entities. Because building greenfield cGMP capacity in North America or Europe requires 3 to 5 years and up to 4x the capital expenditure, mid-to-large Indian CRDMOs (such as Divi's, Syngene, Piramal, and Aragen) have captured an unprecedented wave of global request-for-proposals (RFPs).
• De-Risking the Supply Chain: Tier-1 generic drugmakers in the US and Europe now mandate dual-sourcing requirements for critical starting materials (KSMs), structurally preventing single-country exposure.

3. Domestic Engine: Policy Execution & The Return of Fermentation

Historically, India's vulnerability lay in importing over 65–70% of its key starting materials and basic intermediates from China. The government's multi-pronged industrial policy has altered this trajectory:

• Production Linked Incentive (PLI) Schemes: The Bulk Drug PLI framework has realized over ₹5,210 crore in targeted domestic investments. Domestic facilities for historically import-reliant even for basic molecules—most notably Penicillin G, Clavulanic Acid, and 6-APA, etc etc —have entered commercial production, insulating supply chains from international price volatility.
• Mega Bulk Drug Parks: Three designated central parks in Gujarat, Andhra Pradesh, and Himachal Pradesh have centralized zero-liquid discharge (ZLD) effluent management, steam, and high-voltage power grids. This infrastructure reduces production operating expenses by 18–22%, narrowing the historical margin gap with Chinese competitors.

4. The Value Pivot: From Low-Margin Chemistry to Advanced Modalities

Leading Indian API manufacturers are reallocating capital expenditure from mature, price-eroded small molecules to technically complex chemistries:

1. Peptides and GLP-1 Agonists: Driven by global demand for metabolic and weight-loss drugs (Semaglutide, Tirzepatide), Indian synthesizers have invested in large-scale Solid-Phase Peptide Synthesis (SPPS) and continuous flow purification.
2. High-Potency Containment (HPAPIs): With oncology therapies requiring safe handling at OEB-4 and OEB-5 occupational exposure levels, new manufacturing blocks in Hyderabad and Visakhapatnam are designed to meet stringent global containment standards.
3. Green Chemistry & Flow Reactors: To counter volatile solvent costs and regulatory scrutiny, Indian manufacturers are replacing multi-step batch reactors with continuous flow micro reactors, cutting solvent usage by up to 40% and shortening cycle times by 20%.

5. Strategic Challenges Ahead

Despite rapid expansion, the sector faces several critical headwinds:

• Residual Feedstock Exposure: While synthesis has been repatriated, early-stage petrochemical building blocks and basic chemical precursors still depend on foreign spot markets.
• Capital Intensity vs. Cost of Capital: Upgrading legacy MSME units to modern US FDA/EMA data integrity standards and continuous manufacturing requires continuous capital outlays in a high-interest environment.
• Talent Crunch in Bioprocessing: The shift into complex biologics, mRNA, and fermentation requires specialized bioprocess engineers and downstream purification specialists.

The Strategic Takeaway

The Indian API sector is no longer merely an alternative supplier for low-cost generics. By pairing geopolitical alignment with industrial-scale infrastructure and complex synthetic capabilities, India is anchoring its role as an indispensable node in global healthcare security.

For global pharma innovators, the question is no longer whether to engage Indian API partners, but how quickly they can integrate them into long-term strategic supply chains.

FDA allows emergency use of drug remdesivir for COVID 19

The US Food and Drug Administration on Friday authorized Remdesivir (a nucleoside ribonucleic acid (RNA) polymerase inhibitor) an experimental antiviral drug, for emergency use to treat Covid-19.

The authorization allows the intravenous drug to be distributed to doctors to administer to patients with severe disease.

Many health experts have had high hopes for the drug, which was initially developed by Gilead Sciences to treat Ebola. In past,it was also  used in experiments to treat the coronaviruses SARS and MERS. That early testing gave remdesivir a head start in the race for a treatment to Covid-19.

The NIH trial, called the Adaptive COVID-19 Treatment Trial, included 1,063 patients. The results showed that the median time to recover for patients who randomly received the placebo was 15 days while patients who received remdesivir had a median recovery time of 11 days. Remdesivir also lowered the mortality rate compared to the placebo group, from 11.6 percent to 8 percent.

These results, however, are preliminary. There are at least 19 studies on remdesivir around the world underway or in planning stages, some recruiting thousands of patients. It will be several months before they yield definitive answers, but they will, hopefully, bring the world closer to a working treatment.

Earlier  a randomized trial of the drug in China recently published in the Lancet  found that there was no statistical benefit to taking the drug. The study  was based on a true randomized controlled trial from Wuhan, China, with 237 patients. The study was also peer-reviewed by other scientists. Initially, the authors wanted to include up to 450 patients, but the lockdown imposed in the city meant that patients stopped arriving.

The FDA on 28^th March, 2020  had approved  emergency use authorization to a malaria drug, hydroxychloroquine, after President Donald Trump repeatedly promoted it as a possible treatment for COVID-19. 

Here is the link to the announcement.

US FDA announcement  

Bayer and Monsanto to Create a Global Leader in Agriculture

In the largest deal of 2016 (so far), after months of negotiations  with several  baby steps  agriculture giants Bayer and Monsanto announced  that  they are planning to merge. In an  all-cash   transaction    Bayer  striking the deal a $128  a share  valuing Monsanto at $66B.  including the debt.

Consolidation has been driven by a global  glut that has pushed down crop prices and hurt farm incomes, leading to reduced investment in agricultural inputs such as fertilisers and  Agrochemicals.   Several Mega & small mergers are right now underway/partially completed   like Dow Chemical and DuPont, ChemChina &   Syngenta, FMC & Cheminova  etc.

But the proposed merger  likely face an intense and lengthy regulatory process If the deal closes, it will create a company commanding more than a quarter of the combined world market for seeds and pesticides in the fast-consolidating farm supplies industry.

Both the   company executives claims the  businesses are complimentary & there is very little overlap between them.  However antitrust experts have said regulators  likely  demand the sale of some soybeans, cotton and canola seed assets.

The transaction includes a $2-billion break-up fee that Bayer will pay to Monsanto should it fail to get regulatory clearance. Bayer expects the deal to close by the end of 2017.

CRISIL rings Warning Bell for Indian Pharma Companies

A new Crisil report  made it clear how fast the Indian pharma sector needs to shift away from export-oriented manufacture of generics and the just process improvement  exercise, towards investing in R&D to develop new molecules and biosimilars  

Sellers of copycat drugs in developed markets may see exports fall by 10-12% in the next five years as fewer drugs go off-patent in these markets,  compare to  CAGR  of 19% seen in the last decade. CRISIL Research said. The deceleration likely to be much more post 2020.

Between 2011 and 2015, Indian companies accounted for an average of 37% of all abbreviated new drug application (ANDA) approvals—which enable a company to sell generic versions of innovator molecules —in the US market. This was about  similar   to 40%  share held by US companies, but way ahead of the next competing countries—Israel and Germany—which had 5% each.

Non availability of any   further off patent  block buster  and  fall  in growth rate  of   US generic market, the writing on the wall for Indian drug-makers is clear: They have to move up the value-chain, from making cheap copies of off-patent drugs to creating and owning intellectual property through new discovery and biosimilars. To be sure, they have increased R&D spending significantly over the years. Top 30 companies research spending was 6.5% of revenues in FY15, compared to 3.8%  a decade back. However, this pales in comparison with global majors, who spend close to 16%.

Moreover, the Crisil report points out, much of the Indian companies’ expenditure is  for launching generic therapies, changing product mix in generics, and process development. Besides, the atmosphere of doubt over drug quality—in the wake of the FDA’s crackdown—further dampens Indian generic-makers’ export-prospects. 

CRISIL Research analysis indicates that 14  Indian companies together have 39 products in various stages of clinical development. These companies have adopted various approaches—such as in-house development, joint development and out-licensing—to manage the risk-return trade-off.  However, no one has launched a new molecule in a regulated market such as the US.

Thus far,  it is  disappointing in NCE effort  but  39 product in the pipeline should be an encouraging sign for Indian pharma’s prospects. The key challenge will be to uphold drug-quality and pass the approval hurdles in well-regulated jurisdictions like the US.